Argenx (ARGX)
(Delayed Data from NSDQ)
$499.67 USD
-16.51 (-3.20%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $499.41 -0.26 (-0.05%) 7:58 PM ET
1-Strong Buy of 5 1
F Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$499.67 USD
-16.51 (-3.20%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $499.41 -0.26 (-0.05%) 7:58 PM ET
1-Strong Buy of 5 1
F Value F Growth B Momentum F VGM
Zacks News
Immunovant (IMVT) Focus on Developing Autoimmune Disease Drug
by Zacks Equity Research
Immunovant (IMVT) remains focused on developing its lead pipeline candidate, batoclimab for treating several types of autoimmune diseases. The lack of other pipeline candidates remains a concern.
Best Momentum Stocks to Buy for August 3rd
by Zacks Equity Research
SSB, XOM and ARGX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 3, 2022.
Is McKesson (MCK) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how McKesson (MCK) and argenex SE (ARGX) have performed compared to their sector so far this year.
Is Altimmune (ALT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Altimmune, Inc. (ALT) and argenex (ARGX) have performed compared to their sector so far this year.
Halozyme's (HALO) ENHANZE Drives Stock: Rally to Continue?
by Zacks Equity Research
Halozyme's (HALO) revenues are driven by strong demand for new partnered drugs developed using ENHANZE. Robust revenue growth is expected to continue in 2022.
5 Reasons Why You Should Add Halozyme (HALO) to Your Portfolio
by Zacks Equity Research
We provide five reasons, which make Halozyme (HALO) a good investment option in 2022.
Halzoyme (HALO) Up 8.3% YTD: Will It Continue to Trend Higher?
by Zacks Equity Research
Halozyme's (HALO) revenues are driven by strong demand for new partnered drugs. Restructuring initiatives are boosting margins. Robust revenue growth is expected to continue in 2022.
Halozyme's (HALO) ENHANZE Drives Sales Amid Rising Competition
by Zacks Equity Research
Halozyme (HALO) is attracting partnerships from several large pharma companies as well as biotechs, courtesy of its ENHANZE technology. Royalties and product supply to partners are likely to drive revenues.
argenx (ARGX) Up on Positive Autoimmune Disorder Study Data
by Zacks Equity Research
argenx (ARGX) plans to file a BLA for the SC formulation of efgartigimod, developed using Halozyme's ENHANZE technology, for treating myasthenia gravis disease, an autoimmune disorder, in 2022.
Should You Buy argenx SE (ARGX) Ahead of Earnings?
by Zacks Equity Research
argenx SE (ARGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Materialise (MTLS) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Materialise's (MTLS) fourth-quarter 2021 earnings are likely to have benefited from solid operational performance in all three segments.
Splunk (SPLK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Splunk's (SPLK) fourth-quarter fiscal 2022 performance is likely to have benefited from solid demand for cloud-based solutions and customer additions.
SEMrush (SEMR) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
SEMrush's (SEMR) fourth-quarter 2021 performance is likely to have benefited from growth in user licenses per customer along with strength in product add-ons.
Biotech Stock Roundup: BIIB's Drug Approval, ALXN Drug Label Expansion & More
by Zacks Equity Research
The biotech sector was in focus last week with regulatory updates from Biogen (BIIB) and bluebird (BLUE), among others.
argenx (ARGX) to Regain AML Candidate After J&J's Dismissal
by Zacks Equity Research
argenx (ARGX) is developing cusatuzumab as potential treatment for acute myeloid leukemia. However, its partner, J&J, decided to discontinue the development agreement with the company for the candidate.
Halozyme (HALO) Q3 Earnings Top, 2020 View Up, Stock Rises
by Zacks Equity Research
Halozyme (HALO) reports better-than-expected third-quarter results. The company raises outlook for the year anticipating higher royalties.
Immunovant Up on Positive Data From Myasthenia Gravis Study
by Zacks Equity Research
Immunovant's (IMVT) myasthenia gravis candidate, IMVT-1401, meets endpoints in a mid-stage study.
argenx (ARGX): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
argenx (ARGX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
argenx Up on Positive Data from Pivotal Efgartigimod Study
by Zacks Equity Research
argenx's (ARGX) lead pipeline candidate, efgartigimod, meets primary endpoint in a pivotal study evaluating it in myasthenia gravis. A BLA is likely to be filed by the end of 2020.
Biotech Stock Roundup: REGN's Stake Buyback, INO, NVAX's Coronavirus Updates & More
by Zacks Equity Research
The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.
Halozyme (HALO) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Halozyme (HALO) reports wider-than-expected Q1 loss. Shares down.
Top Ranked Momentum Stocks to Buy for February 27th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, February 27th
Why Earnings Season Could Be Great for argenx (ARGX)?
by Zacks Equity Research
argenx (ARGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Here's Why Momentum Investors Will Love ARGENX SE-ADR (ARGX)
by Zacks Equity Research
Does ARGENX SE-ADR (ARGX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Company News For Dec 12, 2017
by Zacks Equity Research
Companies in the news are: KMG,ARGX,BPMC,BLUE